PTC Therapeutics Honored for Patient Advocacy Efforts By the Genetic Alliance
SOUTH PLAINFIELD, N.J., July 28 /PRNewswire/ — PTC Therapeutics, Inc. (PTC) today announced that the company was awarded the Art of Industry Partnership Award by the Genetic Alliance. Genetic Alliance presents the Art of Listening, Art of Advocacy, and Art of Industry Partnership Awards annually.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )
“The Art of Industry Partnership Award honors a for-profit company that models the benefits of creative partnerships between consumer advocates and industry in advancing understanding and treatment of genetic conditions,” stated Sharon Terry, chief executive of the Genetic Alliance. “PTC Therapeutics has proven itself a leader in establishing productive, effective partnerships between government, advocacy organizations and physicians to advance drug development in areas of high unmet medical need; areas where few other pharmaceutical companies have been willing to focus. We are proud to acknowledge their leadership with this award.”
PTC has established relationships and partnerships with several advocacy groups, including the Muscular Dystrophy Association, the Parent Project Muscular Dystrophy, the Cystic Fibrosis Foundation, the Spinal Muscular Atrophy Foundation, and Fight SMA. Collectively these groups have provided significant funding to support research in multiple genetic disorders. Importantly, the advocacy community has also been essential in helping establishing clinical endpoints and facilitating better understanding the challenges and needs of those affected by genetic disorders. The result of this support is that PTC now has established one of the broadest genetic disorders pipelines in the industry with over eleven programs addressing Duchenne muscular dystrophy, cystic fibrosis, and spinal muscular atrophy.
“We are honored to receive this award from the Genetic Alliance. Our relationships with the advocacy community have been essential in our quest to develop innovative therapeutics in genetic disorders,” stated Stuart W. Peltz, Ph.D., president and chief executive officer of PTC Therapeutics. “We look forward to continuing these valuable and productive collaborations with advocacy groups as well as the broader patient community.”
About Genetic Alliance
Genetic Alliance transforms health through genetics, using an environment of openness centered on the health of individuals, families, and communities. Genetic Alliance brings together diverse stakeholders that create novel partnerships in advocacy; integrates individual, family, and community perspectives to improve health systems; and revolutionizes access to information to enable translation of research into services and individualized decision making.
About PTC Therapeutics Inc.
PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC’s internally-discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology and infectious diseases. In addition, PTC has developed proprietary technologies and extensive knowledge of post-transcriptional control processes that it applies in its drug discovery and development activities, including the Gene Expression Modulation by Small-molecules (GEMS) technology platform, which has been the basis for collaborations with leading pharmaceutical and biotechnology companies such as Genzyme, Pfizer, Celgene, CV Therapeutics and Schering-Plough. For more information, visit PTC’s website, http://www.ptcbio.com/.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.com
PTC Therapeutics, Inc.
CONTACT: Investors and Media, Jane Baj, PTC Therapeutics, Inc.,+1-908-912-9167, jbaj@ptcbio.com; Sheryl Seapy, Pure Communications,+1-949-608-0841, sheryl@purecommunicationsinc.com, for PTC
Web site: http://www.ptcbio.com/